ArticleCureus2026
Clinical Characteristics and Delays in the Care Pathway of Patients With Lung Cancer Treated at a Public Hospital in Costa Rica, 2015-2020.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDelays in the lung cancer care pathway and limited access to molecular biomarkers, targeted therapies, and immunotherapy may affect diagnosis, treatment opportunities, and survival. This study described the clinical profile, care pathway delays, biomarker testing, treatment access, and survival of patients with primary lung cancer treated at a public hospital in Costa Rica.
methodsWe conducted a retrospective observational study based on medical record review. Adult patients with a pathological diagnosis of primary lung cancer treated at a public tertiary-level hospital in Costa Rica between 2015 and 2020 were included (n=223). Clinical, sociodemographic, and care process variables were analyzed, including symptoms at the time of consultation, smoking history, diagnostic and therapeutic time intervals, molecular biomarker testing, treatments received, and survival from the first care episode related to suspected lung cancer until death or the end of follow-up.
resultsThe most frequent symptoms before diagnosis were cough (n=126; 56.50%), dyspnea (n=110; 49.33%), and weight loss (n=98; 43.95%). The median time between documented suspicion and pathological diagnosis was 34 days (IQR: 21-73; n=213), although extreme values exceeding 1000 days were observed. Molecular biomarker testing was recorded in 106 patients (47.53%), and targeted therapy or immunotherapy was documented in 45 patients (30.00%). Among patients who received targeted therapy or immunotherapy, 29 (64.44%) accessed these treatments through administrative requests to higher institutional authorities outside the standard care protocol. The estimated five-year survival from the first care episode related to suspected lung cancer was 1.9% (95% CI: 0.5-5.1).
conclusionsThis cohort showed frequent diagnostic delays, high variability in care pathway intervals, limited access to molecular biomarkers and innovative therapies, and low five-year survival from the first care episode related to suspected lung cancer. These findings support the need to strengthen suspicion, referral, timely diagnosis, and equitable access to diagnostic technologies and therapeutic alternatives for patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.